Rejuvenate Biomed, a biomedical company, researches the biology of aging & applies this knowledge to develop safe and synergistic combination drugs to maintain and restore our natural cellular resilience, postponing the onset of age-related diseases.
Biology of aging
Major progress has been made in the biology of aging, also known as geroscience. This has resulted in a better scientific understanding of the biological processes associated with age-related functional decline. Several mechanisms (hallmarks of aging1 & hallmarks of health2) have been elucidated and drugable targets have been identified. At Rejuvenate Biomed, we identify opportunities to impact the aging process and develop new synergistic combination drugs that can positively influence cell health (mitochondrial, autophagy, ...), cell-cell communication and the immune system response.
Within our in silico selection model, we make use of large datasets and apply network biology to evaluate safe prescription drugs. We combine these building blocks into new synergistic combination drugs that can restore complex biological systems. Our selection criteria contain, amongst others, human safety and efficacy potential to influence a curated list of genes. Our portfolio currently over 10 promising building blocks which have been selected via our platform. For our lead candidate RJx-01, we have generated positive preclinical data, supportive to treat and prevent sarcopenia (muscle failure) as a first age-related disease with a huge impact on quality of life. We are currently preparing RJx-01 for a clinical Proof of Concept study, that we plan to start in 2021. RJx-02 will be defined in 2021 as well.
Our lead RJx-01
Chronic sarcopenia is the progressive age-associated loss of muscle function and mass and starts to manifest around the age of 50y, with muscle strength being lost at ~3% per year and mass at ~0.5-1.2% per year. This contributes to negative health outcomes, including an increased risk for disability, falls and fractures. Bedrest and hospitalization for an acute illness or surgery causes the acute development of sarcopenia due to an increased inflammatory burden in combination with muscle disuse (acute sarcopenia). The prevalence of sarcopenia in post-acute inpatient rehabilitation is 50%. Acute sarcopenia may be (partially) recoverable but increases the risk of chronic sarcopenia. Therefore, targeted interventions to prevent or reverse the effects are crucial. Preclinically, additional age-related indications have been identified as opportunities for RJx-01 to make a difference to people.
Acknowledgements and Investors
Rejuvenate Biomed is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
Flanders Innovation & Entrepreneurship supports innovation and entrepreneurship, and contributes to a favorable business climate in Flanders.
Vesalius Biocapital is a European life sciences venture capital investor. The active fund Vesalius Biocapital III had a final closing in May 2019 with € 120 million in commitments.
BAN Vlaanderen is a business angel network, that brings together starting or growing entrepreneurs looking for risk capital with informal private investors.